Skip to main content
NUVL logo

NUVL

Nuvalent, Inc. Class A

$123.96

0.02%

Trade Ideas Performance

Latest Closed Trade Idea

$123.96

0.02%
Loading...
We are loading your data. Please wait a moment.

Sentiment

News

34

Social

0

About

Events of Nuvalent, Inc. Class A (NUVL)

The FDA's acceptance of NDAs for zidesamtinib and neladalkib has positively impacted Nuvalent's stock. Positive data from the ARROS-1 and ALKOVE-1 clinical trials were presented at WCLC 2025 and ASCO 2026, respectively. A strategic collaboration with Guardant Health for oncology drug development was viewed positively. Nuvalent reported a wider net loss for Q1 2026 due to increased R&D expenses, but ended the quarter with $1.3 billion in cash, projected to fund operations into 2029. There has been a notable wave of insider selling in recent months.

Read more

FAQ

Related Assets

Price action provided by Massive. Fundamentals, news and corporate events provided by FactSet. NLP support provided by Perplexity & Gemini. All data is provided for informational purposes only.

Make every trade make sense.

Sign up free. No card required. Three trade ideas a day, the AI analyst, the community - on us.

Get started for FREE (opens in new tab)
Edge Hound mobile app preview on iPhone

Join us and trade with people
who think like you.

The Edge Hound Discord is where serious self-directed investors talk strategy, share setups, and learn from each other. Free to join with any plan - including Free.

Free to join with any plan - including Free.

Join our Discord community (opens in new tab)
Nuvalent, Inc. (NUVL) Live Stock Price, Chart & Financial News | Edge Hound